Compare NN & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NN | CDNA |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | 103 | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 1.1B |
| IPO Year | N/A | 2007 |
| Metric | NN | CDNA |
|---|---|---|
| Price | $21.20 | $20.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $25.00 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 3.3M | 733.8K |
| Earning Date | 05-14-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | N/A | $16.01 |
| Revenue Next Year | N/A | $11.31 |
| P/E Ratio | ★ N/A | $409.60 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $10.84 | $10.96 |
| 52 Week High | $24.19 | $23.24 |
| Indicator | NN | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 60.91 | 47.72 |
| Support Level | $13.79 | $16.63 |
| Resistance Level | $24.19 | $21.20 |
| Average True Range (ATR) | 1.22 | 1.33 |
| MACD | 0.26 | -0.22 |
| Stochastic Oscillator | 87.66 | 38.34 |
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system delivers resilient, next-generation, complementary positioning, navigation, and timing (PNT) solutions designed to overcome the limitations and vulnerabilities of existing space-based Global Navigation Satellite Systems (GNSS), including the Global Positioning System (GPS). The products of the company include NextNav Pinnacle: Accurate vertical location, NextNav 3D: 3D location visualization, NextNav TerraPoiNT: Resilient PNT for 3D and indoor geolocation, Next Generation Solution: Terrestrial 3D PNT powered by spectrum.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.